drugset
drugset / Trial / NCT06673498

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

NCT06673498 ↗

Phase 2 Recruiting 60 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.

Timeline

Start
2024-11-10
Primary completion
2025-11-30
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lusutrombopag Small molecule — —
Subject recombinant human thrombopoietin Protein / enzyme biologic — —

Indications

thrombocytopenia